Stark II's second phase limits brachytherapy referrals

Lithotripsy is generally excluded, but watch for indirect financial relationships

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria